NEW YORK – Reproductive genetics researchers at Columbia University Medical Center (CUMC) are leading a multicenter prospective clinical study investigating the effects of chromosomal abnormalities (duplicative or missing material) found prenatally through microarray analysis. The goal of the study is to gain further information on genetic variances previously not well reported in the medical literature and share it with parents during pregnancy.
Led by principal investigator Ronald J. Wapner, MD, professor and vice chair for research at CUMC’s Department of Obstetrics and Gynecology and director of reproductive genetics at NewYork-Presbyterian Hospital/Columbia, the research is the next phase of a project to advance clinicians’ ability to diagnose in utero conditions such as developmental delays, structural abnormalities, and treatable or life-threatening diseases.
“Parents of children found to have a genetic variance want a better understanding of what it means. Our goal is to give them as much information and support as possible—from detailed genetic counseling to ways to connect with other people expecting children with the same variance,” said Dr. Wapner.
In December 2012, Dr. Wapner and colleagues published in the New England Journal of Medicine (NEJM) findings of a trial involving 4,400 patients at 29 centers nationwide. That study showed that microarray analysis of a fetus’s DNA gave significantly more clinically relevant information than the standard method of analysis, known as karyotyping—a visual analysis of the fetus’s chromosomes. [Click here for a news release about that study.]
In the current study—which has ongoing clinical recruitment—data on babies included in the NEJM article will be augmented by data on patients recruited by 10 major prenatal diagnostic centers around the country that offer microarray to all their patients. Each center aims to recruit 1,000 patients. Of the anticipated 10,000 or so microarray analyses, the researchers aim to follow 300–600 children born with genetic variances, for at least three years. (See below for more about microarray.)
“While the majority of abnormalities found with microarray are associated with known conditions, in many cases the full implications of findings are not well understood, and about 1.5 percent are unidentified. The goal is to fill in these knowledge gaps,” said Dr. Wapner.
“Ours is the only study of its kind that is identifying genetic variances in utero and following the kids over time to see how the abnormalities present and to gather as much clinical information about them as possible, such as the severity of problems and life expectancy,” said Dr. Wapner.
“When we counsel parents now, we can give them only limited information, drawn from what we know about children who have undergone genetic testing. But these children often represent the severe end of the spectrum,” said Dr. Wapner. “There might be people who, because they had no symptoms, were never identified as having a variance, limiting the prognostic information we are able to give parents.”
NewYork-Presbyterian/Columbia is the primary recruitment center. The other centers participating in the study are: the Center for Fetal Medicine, Northwestern University, Cedars Sinai Medical Center, San Francisco Perinatal, Carnegie Hill Imaging, Montefiore Medical Center, Mount Sinai Medical Center, Lenox Hill, and North Shore LIJ.
A majority of the labs in the country that do prenatal microarray have agreed to refer patients to the website, where they will be able to self-enroll in the study. “We hope to capture almost all the available microarray data,” said Dr. Wapner.
Website to Collect, Share Information in Real Time with Parents, Clinicians
Trial data will be collected and shared in real time with parents and clinicians via the website www.prenatalarray.org, where expectant parents undergoing testing can learn how microarray works and what it looks for; parents of a child with a variance can find information about their baby’s variance and connect with other parents of babies with the same variance; and physicians, genetic counselors, and other clinicians can input and research real-time information on the clinical impact of the variance.
“We will link genetic anomalies with structural abnormalities—connecting the genotype (the genetics, or errors) with the phenotype (what you see),” said Dr. Wapner. “This will help us to better understand the basis of birth defects—things that run together, what genes to look for, and so on.”
Software to better categorize ultrasound findings and relate them to the phenotype is provided by a genetics software-as-a-service company called Cartagenia, a collaborator on this work. As medical science continues to advance, Dr. Wapner and his colleagues hope and expect that this data pool (and web tracking system) will continue to improve genetic surveillance.
A web-based portal designed and hosted by David Ledbetter, PhD, and W. Andrew Faucett, MS, collaborators at Geisinger Health System in Danville, Pa., enables secure two-way communication with patients. This allows researchers to conduct surveys about patients’ attitudes and opinions about testing; it can also help them to understand how the patients dealt with learning that their child has a genetic variance.
More About Microarray
Microarray requires fetal cells obtained through an invasive procedure (offered to high-risk pregnant women), such as amniocentesis, in which fetal cells are taken from the amniotic fluid, or chorionic villus sampling, in which cells are taken from the placenta. Pregnant women are deemed high risk if they have advanced maternal age (age 35 or older) or if their fetuses are shown through early screening to be at increased risk for Down syndrome, to have structural abnormalities (as seen with ultrasound), or to have indications of other problems. Parents deciding whether to undergo these tests must weigh a number of factors, including their individual risk of fetal abnormalities, possible procedure-induced miscarriage, and the consequences of having an affected child.
Wendy Chung, MD, PhD, associate professor of pediatrics (in medicine) at Columbia University Medical Center and director of clinical genetics at NewYork-Presbyterian/Columbia, is supervising the evaluation of the children.
The data are being housed at the George Washington University data center. Researchers at the University of Pennsylvania are leading the counseling and psycho-social portions of the study.
Additional members of the steering committee for this study include: Elizabeth Thom, PhD and Rebecca Clifton, PhD (George Washington University); Frances K. Barg, PhD and Barbara Bernhardt, MS (University of Pennsylvania); Laird Jackson, MD (Drexel University); Steven Van Vooren, PhD (Cartagenia); Brynn Levy, PhD (CUMC); Art Beaudet, MD, PhD (Baylor College of Medicine); Lisa Shaffer, PhD (Signature/Perkin Elmer); Jon Hart (Lab Corp); Christa Martin, PhD (Geisinger); Reed Pyeritz, MD, PhD (Penn Center for the Integration of Genetic Healthcare Technologies); Joe Leigh Simpson, MD (Florida International University); and Mike Watson, PhD (American College of Medicine Genetics).
This research is supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH Grant No. 2U01HD055651-06; Project No. GG006961).
The authors declare no financial or other conflicts of interest.
Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.
NewYork-Presbyterian Hospital, based in New York City, is one of the nation’s largest and most comprehensive hospitals, with 2,589 beds. In 2012, the Hospital had nearly 2 million inpatient and outpatient visits, including 12,758 deliveries and 215,946 visits to its emergency departments. NewYork-Presbyterian’s 6,144 affiliated physicians and 20,154 staff provide state-of-the-art inpatient, ambulatory and preventive care in all areas of medicine at six major centers: NewYork-Presbyterian Hospital/Weill Cornell Medical Center, NewYork-Presbyterian Hospital/Columbia University Medical Center, NewYork-Presbyterian/Morgan Stanley Children’s Hospital, NewYork-Presbyterian/The Allen Hospital, NewYork-Presbyterian Hospital/Westchester Division and NewYork-Presbyterian/Lower Manhattan Hospital. One of the most comprehensive health care institutions in the world, the Hospital is committed to excellence in patient care, research, education and community service. NewYork-Presbyterian is the #1 hospital in the New York metropolitan area and is consistently ranked among the best academic medical institutions in the nation, according to U.S. News & World Report. The Hospital has academic affiliations with two of the nation’s leading medical colleges: Weill Cornell Medical College and Columbia University College of Physicians and Surgeons. For more information, visit www.nyp.org.
Media Contact Only:
Elizabeth Streich, 212-305-3689, firstname.lastname@example.org